Dimensional Fund Advisors LP Has $40.35 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Dimensional Fund Advisors LP grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 13.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 255,396 shares of the biotechnology company’s stock after purchasing an additional 31,105 shares during the period. Dimensional Fund Advisors LP owned about 0.27% of Sarepta Therapeutics worth $40,353,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SRPT. WINTON GROUP Ltd acquired a new position in Sarepta Therapeutics during the second quarter worth $425,000. Envestnet Asset Management Inc. increased its holdings in Sarepta Therapeutics by 69.1% during the second quarter. Envestnet Asset Management Inc. now owns 68,679 shares of the biotechnology company’s stock worth $10,851,000 after buying an additional 28,073 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in Sarepta Therapeutics by 19.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 4,312 shares of the biotechnology company’s stock worth $681,000 after buying an additional 708 shares during the last quarter. Westover Capital Advisors LLC acquired a new position in Sarepta Therapeutics during the second quarter worth $415,000. Finally, Meeder Asset Management Inc. increased its holdings in Sarepta Therapeutics by 1,490.9% during the second quarter. Meeder Asset Management Inc. now owns 525 shares of the biotechnology company’s stock worth $83,000 after buying an additional 492 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Price Performance

SRPT opened at $124.89 on Tuesday. The firm has a market cap of $11.81 billion, a price-to-earnings ratio of 1,135.36 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The stock’s 50 day simple moving average is $134.56 and its 200 day simple moving average is $132.86.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same period in the prior year, the business posted ($0.27) EPS. The firm’s revenue was up 38.9% compared to the same quarter last year. As a group, analysts predict that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have commented on SRPT. Evercore ISI upgraded shares of Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and decreased their price objective for the company from $185.00 to $179.00 in a report on Thursday, August 8th. Needham & Company LLC reissued a “buy” rating and issued a $235.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, June 27th. UBS Group boosted their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Morgan Stanley reaffirmed an “overweight” rating and set a $165.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, June 21st. Finally, Bank of America upped their price objective on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. Three equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $187.39.

Insider Activity at Sarepta Therapeutics

In related news, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael Andrew Chambers acquired 37,038 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.